湖北英纳氏生物科技有限公司是一家在小分子药物研发领域,为药物研发与产业化机构提供研发与产业化服务的CDMO(合同研发生产)企业。公司现有业务包括医药中间体和流动化学相关工艺的研发和生产。公司主要产品包括:外用消炎杀菌类小分子药物本维莫德、克立硼罗、可比落、米诺地尔及其中间体,医学荧光检测示踪剂D-荧光素及钠盐钾盐,阳离子脂质体SM-102、Lipid 5、ALC-0315及相关中间体,苯环和杂环类分子砌块。公司专注于微反应器连续工艺开发及工业化,新建了适应不同生产能力的流动化学实验室,另外配套年流通2000吨的连续流微反应器设备和生产车间,可实现流动化学从小试、中试到商业化生产的一条龙服务,从工艺到设备的一站式服务。 Hubei Innerse Biotechnology Co., Ltd. is a CDMO (Contract Research and Development Production) enterprise that provides research and industrialization services for drug development and industrialization institutions in the field of small molecule drug research and development. The company's current business includes the research and production of pharmaceutical intermediates and flow chemistry related processes. The company's main products include: topical anti-inflammatory and bactericidal small molecule drugs Benvimod, Kriborol, Kobilol, Minodil and their intermediates, medical fluorescence detection tracer D-fluorescein and sodium potassium salt, cationic liposomes SM-102, Lipid 5, ALC-0315 and related intermediates, benzene ring and heterocyclic molecular blocks. The company focuses on the continuous process development and industrialization of microreactors, and has built a flow chemistry laboratory that can adapt to different production capacities. In addition, it is equipped with continuous flow microreactor equipment and production workshops with an annual circulation of 2000 tons, which can achieve a one-stop service from small-scale and pilot scale to commercial production of flow chemistry, from process to equipment.